Piramal Critical Care launches Chlorpromazine Hydrochloride for Injection in US
Bethlehem: Piramal Critical Care (PCC), a division of Piramal Pharma Limited has announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials .
With this launch, PCC continues to expand their generic injectables porƞolio.
Peter DeYoung, Chief Executive Officer, Piramal Global Pharma commented, “We are excited to launch Chlorpromazine Hydrochloride for Injection, USP, which joins our growing US porƞolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”
Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Their product portfolio includes inhaled anesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. Piramal Critical Care has manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations.
